Robert B Zipursky

List of Publications by Year
in descending order

121 papers	9,377 citations	31976 53 h-index	38395 95 g-index
123 all docs	123 docs citations	123 times ranked	7383 citing authors

#	Article	IF	Citations
1	Brain Gray and White Matter Volume Loss Accelerates with Aging in Chronic Alcoholics: A Quantitative MRI Study. Alcoholism: Clinical and Experimental Research, 1992, 16, 1078-1089.	2.4	525
2	Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal of Psychiatry, 2006, 163, 790-799.	7.2	500
3	Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol. American Journal of Psychiatry, 2003, 160, 1396-1404.	7.2	380
4	5-HT₂and D₂Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. American Journal of Psychiatry, 1998, 155, 921-928.	7.2	359
5	The Myth of Schizophrenia as a Progressive Brain Disease. Schizophrenia Bulletin, 2013, 39, 1363-1372.	4.3	274
6	Pregnancy Outcome of Women Using Atypical Antipsychotic Drugs. Journal of Clinical Psychiatry, 2005, 66, 444-449.	2.2	267
7	Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 2000, 152, 174-180.	3.1	249
8	A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophrenia Research, 2006, 88, 26-35.	2.0	236
9	A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research, 2011, 125, 54-61.	2.0	209
10	The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. Life Sciences, 1995, 57, PL103-PL107.	4.3	204
11	Volumetric MRI assessment of temporal lobe structures in schizophrenia. Biological Psychiatry, 1994, 35, 501-516.	1.3	203
12	The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence. Neuropsychopharmacology, 2008, 33, 473-479.	5.4	195
13	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 2003, 54, 453-464.	1.3	194
14	Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment. American Journal of Psychiatry, 2005, 162, 939-946.	7.2	193
15	Factors of the Wisconsin Card Sorting Test as measures of frontal-lobe function in schizophrenia and in chronic alcoholism. Psychiatry Research, 1993, 46, 175-199.	3.3	183
16	Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. British Journal of Psychiatry, 2005, 187, 537-543.	2.8	183
17	Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. Schizophrenia Research, 2014, 152, 408-414.	2.0	172
18	Cerebral white matter deficiencies in pedophilic men. Journal of Psychiatric Research, 2008, 42, 167-183.	3.1	159

#	Article	IF	Citations
19	Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. Journal of Pediatrics, 1996, 129, 794-803.	1.8	154
20	Equivalent Occupancy of Dopamine D₁and D₂Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics. American Journal of Psychiatry, 2004, 161, 1620-1625.	7.2	146
21	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry, 2004, 185, 18-24.	2.8	143
22	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D₂Receptors: a PET Study in Schizophrenia. American Journal of Psychiatry, 2007, 164, 630-637.	7.2	141
23	Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research, 2006, 83, 53-63.	2.0	135
24	The relationship between D 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 1997, 131, 148-152.	3.1	118
25	Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Responseâ€"A Double-Blind PET Study in Schizophrenia. Neuropsychopharmacology, 2007, 32, 1209-1215.	5.4	118
26	Cognitive Function and Brain Structure in Females With a History of Adolescent-Onset Anorexia Nervosa. Pediatrics, 2008, 122, e426-e437.	2.1	117
27	Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology, 2019, 44, 1036-1042.	5.4	116
28	Qualitative MRI findings in adults with 22q11 deletion syndrome and schizophrenia. Biological Psychiatry, 1999, 46, 1436-1442.	1.3	115
29	Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970â€"2010. American Journal of Psychiatry, 2013, 170, 1335-1344.	7.2	112
30	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study. Neuropsychopharmacology, 2009, 34, 1078-1086.	5.4	109
31	Serotonin 5-HT₂Receptors in Schizophrenia: A PET Study Using [¹⁸F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects. American Journal of Psychiatry, 1999, 156, 72-78.	7.2	108
32	Structural brain abnormalities in patients with schizophrenia and 22q11 deletion syndrome. Biological Psychiatry, 2002, 51, 208-215.	1.3	103
33	Deficits in gray matter volume are present in schizophrenia but not bipolar disorder1This work was presented at the Meeting of the Society of Biological Psychiatry, Philadelphia, PA, USA, May 1994.1. Schizophrenia Research, 1997, 26, 85-92.	2.0	101
34	Increased Dopamine D₂Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. American Journal of Psychiatry, 2001, 158, 311-314.	7.2	99
35	A deficit profile of executive, memory, and motor functions in schizophrenia. Biological Psychiatry, 1994, 36, 641-653.	1.3	94
36	PET Evidence That Loxapine Is an Equipotent Blocker of 5-HT₂and D₂Receptors: Implications for the Therapeutics of Schizophrenia. American Journal of Psychiatry, 1997, 154, 1525-1529.	7.2	92

#	Article	IF	Citations
37	Substance Use and Abuse in First-Episode Psychosis: Prevalence Before and After Early Intervention. Schizophrenia Bulletin, 2006, 33, 1354-1363.	4.3	89
38	MRI Study of Brain Changes with Short-Term Abstinence from Alcohol. Alcoholism: Clinical and Experimental Research, 1989, 13, 664-667.	2.4	84
39	Early Use of Clozapine for Poorly Responding First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2007, 27, 369-373.	1.4	82
40	Starving the brain: Structural abnormalities and cognitive impairment in adolescents with anorexia nervosa. Seminars in Clinical Neuropsychiatry, 2001, 6, 146-152.	1.9	80
41	Temporal horn enlargement is present in schizophrenia and bipolar disorder. Biological Psychiatry, 1998, 44, 418-422.	1.3	79
42	PET and SPECT Imaging in Psychiatric Disorders. Canadian Journal of Psychiatry, 2007, 52, 146-157.	1.9	79
43	Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research, 2008, 105, 1-9.	2.0	79
44	Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacology Biochemistry and Behavior, 2003, 74, 425-432.	2.9	76
45	Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade. Journal of Clinical Psychiatry, 2002, 63, 992-997.	2.2	71
46	Is amoxapine an atypical antipsychotic? positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biological Psychiatry, 1999, 45, 1217-1220.	1.3	70
47	Pharmacotherapy of first-episode schizophrenia. British Journal of Psychiatry, 1998, 172, 66-70.	2.8	68
48	Use of Atypical Antipsychotics During Pregnancy and the Risk of Neural Tube Defects in Infants. American Journal of Psychiatry, 2002, 159, 136-137.	7.2	65
49	The effect of antipsychotic treatment on Theory of Mind. Psychological Medicine, 2007, 37, 595.	4.5	64
50	In vivo quantification of the limbic system using MRI: Effects of normal aging. Psychiatry Research - Neuroimaging, 1990, 35, 15-26.	1.8	60
51	Cortical gray matter volume deficits in schizophrenia: a replication. Schizophrenia Research, 1996, 20, 157-164.	2.0	57
52	Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. Biological Psychiatry, 1996, 39, 234-240.	1.3	56
53	Functional network differences in schizophrenia. NeuroReport, 1998, 9, 1697-1700.	1.2	55
54	The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophrenia Research, 2006, 88, 111-118.	2.0	52

#	Article	IF	Citations
55	The contribution of constructional accuracy and organizational strategy to nonverbal recall in Schizophrenia and chronic alcoholism. Biological Psychiatry, 1992, 32, 312-333.	1.3	51
56	Volumetric assessment of cerebral asymmetry from CT scans. Psychiatry Research - Neuroimaging, 1990, 35, 71-89.	1.8	49
57	A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Research - Neuroimaging, 2000, 99, 123-135.	1.8	49
58	MRI-targeted repetitive transcranial magnetic stimulation of Heschlâ€™s gyrus for refractory auditory hallucinations. Brain Stimulation, 2012, 5, 577-585.	1.6	48
59	Neuroimaging studies of schizophrenia. Schizophrenia Research, 1991, 4, 193-208.	2.0	45
60	Happiness in first-episode schizophrenia. Schizophrenia Research, 2012, 141, 98-103.	2.0	45
61	A quantitative analysis of CT and cognitive measures in normal aging and Alzheimer's disease. Psychiatry Research - Neuroimaging, 1990, 35, 115-136.	1.8	43
62	Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation. Psychopharmacology, 2003, 170, 255-262.	3.1	43
63	Why Are the Outcomes in Patients With Schizophrenia So Poor?. Journal of Clinical Psychiatry, 2014, 75, 20-24.	2.2	42
64	Reshaping an enduring sense of self: the process of recovery from a first episode of schizophrenia. Microbial Biotechnology, 2010, 4, 243-250.	1.7	41
65	MRI correlates of treatment response in first episode psychosis. Schizophrenia Research, 1998, 30, 81-90.	2.0	35
66	Early detection of psychosis: finding those at clinical high risk. Microbial Biotechnology, 2008, 2, 147-153.	1.7	33
67	Recovery, not progressive deterioration, should be the expectation in schizophrenia. World Psychiatry, 2015, 14, 94-96.	10.4	33
68	An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Research, 1998, 81, 333-339.	3.3	32
69	Volumetric MRI measurement of caudate nuclei in antipsychotic-naÃ¯ve patients suffering from a first episode of psychosis. Journal of Psychiatric Research, 2005, 39, 365-370.	3.1	32
70	Caudate volume changes in first episode psychosis parallel the effects of normal aging: a 5-year follow-up study. Schizophrenia Research, 2002, 58, 185-188.	2.0	31
71	Deficits in automatically detecting changes in conjunction of auditory features in patients with schizophrenia. Psychophysiology, 2002, 39, 599-606.	2.4	31
72	Adolescents with Anorexia Nervosa: The Impact of the Disorder on Bones and Brains. Annals of the New York Academy of Sciences, 1997, 817, 127-137.	3.8	30

#	Article	IF	Citations
73	How antipsychotics work: The patients' perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 859-864.	4.8	30
74	Increasing D2 affinity results in the loss of clozapineÊ¼s atypical antipsychotic action. NeuroReport, 2002, 13, 831-835.	1.2	29
75	A randomised controlled trial of a group intervention to reduce engulfment and self-stigmatisation in first episode schizophrenia. Australian E-Journal for the Advancement of Mental Health, 2007, 6, 212-220.	0.2	28
76	Treating young individuals at clinical high risk for psychosis. Microbial Biotechnology, 2012, 6, 60-68.	1.7	27
77	Testâ€"retest reliability and stability of N400 effects in a word-pair semantic priming paradigm. Clinical Neurophysiology, 2013, 124, 667-674.	1.5	26
78	Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D₂ Receptor Occupancy in First-Episode Psychosis. Canadian Journal of Psychiatry, 2005, 50, 462-469.	1.9	24
79	Inconsistency in the relationship between duration of untreated psychosis (DUP) and negative symptoms: Sorting out the problem of heterogeneity. Schizophrenia Research, 2007, 93, 152-159.	2.0	24
80	Electrophysiological evidence for primary semantic memory functional organization deficits in schizophrenia. Psychiatry Research, 2012, 196, 171-180.	3.3	24
81	The Relationship Between Risperidone Plasma Levels and Dopamine D (2) Occupancy. Journal of Clinical Psychopharmacology, 1998, 18, 82-83.	1.4	23
82	A â€˜navigatorâ€™ model in emerging mental illness?. Microbial Biotechnology, 2013, 7, 451-457.	1.7	22
83	Modeling the mental health service utilization decisions of university undergraduates: A discrete choice conjoint experiment. Journal of American College Health, 2017, 65, 389-399.	1.5	22
84	Brain Size in Schizophrenia. Archives of General Psychiatry, 1991, 48, 179.	12.3	20
85	Auditory feature conjunction in patients with schizophrenia. Schizophrenia Research, 2001, 49, 179-191.	2.0	19
86	Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. Schizophrenia Research, 1997, 25, 71-78.	2.0	18
87	Preferences for Early Intervention Mental Health Services: A Discrete-Choice Conjoint Experiment. Psychiatric Services, 2016, 67, 184-191.	2.0	18
88	Visual feature conjunction in patients with schizophrenia: an event-related brain potential study. Schizophrenia Research, 2002, 57, 69-79.	2.0	17
89	Event-related brain potential study of semantic priming in unaffected first-degree relatives of schizophrenia patients. Schizophrenia Research, 2014, 153, 78-86.	2.0	16
90	Stable deficits in gray matter volumes following a first episode of schizophrenia. Schizophrenia Research, 2004, 71, 515-516.	2.0	14

#	Article	IF	Citations
91	Depth-of-processing effects on semantic activation deficits in schizophrenia: An electrophysiological investigation. Schizophrenia Research, 2011, 133, 91-98.	2.0	14
92	Examining the Effects of Enhanced Funding for Specialized Community Mental Health Programs on Continuity of Care. Canadian Journal of Community Mental Health, 2010, 29, 23-40.	0.4	14
93	Understanding and Managing Treatment Adherence in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2019, , .	1.4	13
94	Characterizing outcome preferences in patients with psychotic disorders: a discrete choice conjoint experiment. Schizophrenia Research, 2017, 185, 107-113.	2.0	12
95	You say â€œschizophreniaâ€•and I say â€œpsychosisâ€• Just tell me when I can come off this medication. Schizophrenia Research, 2020, 225, 39-46.	2.0	11
96	Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Psychopharmacology, 1994, 116, 291-296.	3.1	10
97	The role of maintenance pharmacotherapy in achieving recovery from a first episode of schizophrenia. International Review of Psychiatry, 2002, 14, 284-292.	2.8	10
98	Illness Intrusiveness and Subjective Well-Being in Schizophrenia. Journal of Nervous and Mental Disease, 2008, 196, 798-805.	1.0	9
99	Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study. Psychopharmacology, 2013, 225, 95-104.	3.1	9
100	Values in First-Episode Schizophrenia. Canadian Journal of Psychiatry, 2015, 60, 507-514.	1.9	8
101	Improving outcomes in schizophrenia by preventing early relapses. Lancet Psychiatry,the, 2018, 5, 384-386.	7.4	8
102	Rethinking service design for youth with mental health needs: The development of the Youth Wellness Centre, St. Joseph's Healthcare Hamilton. Microbial Biotechnology, 2020, 14, 365-372.	1.7	7
103	New insights into schizophrenia from neuroimaging. Current Opinion in Psychiatry, 1998, 11, 33-37.	6.3	7
104	4: Effects of menstrual function and weight restoration on cognitive function in females with adolescent-onset anorexia nervosa. Journal of Adolescent Health, 2007, 40, S12.	2.5	5
105	Investigating service features to sustain engagement in early intervention mental health services. Microbial Biotechnology, 2019, 13, 241-250.	1.7	5
106	APA Practice Guideline for Schizophrenia: Risperidone Equivalents. American Journal of Psychiatry, 1998, 155, 1301a-1302.	7.2	4
107	Clinical and neuropsychologic characteristics of schizophrenics showing impairment on the luria-nebraska neuropsychological battery. Schizophrenia Research, 1989, 2, 61.	2.0	3
108	Imaging Mental Disorders in the 21st Century. Canadian Journal of Psychiatry, 2007, 52, 133-134.	1.9	3

#	Article	IF	Citations
109	Specialized home treatment versus hospitalâ€based outpatient treatment for firstâ€episode psychosis: a randomized clinical trial. Microbial Biotechnology, 2009, 3, 304-311.	1.7	3
110	Rapid remission of first-episode schizophrenia with standardised treatment. Lancet Psychiatry,the, 2018, 5, 770-771.	7.4	2
111	Volumetric MRI study of first episode schizophrenia. Schizophrenia Research, 1997, 24, 161.	2.0	1
112	Ethical issues in schizophrenia research. Current Psychiatry Reports, 1999, 1, 13-19.	4.5	1
113	Specialised care for early psychosis may reduce number of readmissions. Evidence-Based Mental Health, 2005, 8, 34-34.	4.5	1
114	Gender, age, ethnicity and area of residence influence incidence of psychotic disorders. Evidence-Based Mental Health, 2006, 9, 107-107.	4.5	1
115	Imagining schizophrenia without relapses. Australian and New Zealand Journal of Psychiatry, 2017, 51, 764-765.	2.3	1
116	Modeling the Reduction of Attrition in Campus Mental Health Services: A Discrete Choice Conjoint Experiment. Emerging Adulthood, 2020, , 216769682094689.	2.4	1
117	Motivational Enhancement as a Pretreatment to a Transdiagnostic Intervention for Emerging Adults with Emotion Dysregulation: A Pilot Randomized Controlled Trial. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 132-148.	0.6	1
118	Psychotic Recurrence After Antipsychotic Discontinuation. American Journal of Psychiatry, 2002, 159, 1441-a-1442.	7.2	0
119	Do anxiety and depression symptoms moderate the effect of motivational enhancement therapy as a pretreatment to dialectical behaviour therapy skills training? A followâ€up analysis of a pilot randomised controlled trial for youth. Microbial Biotechnology, 2021, , .	1.7	0
120	Alvin Zipursky (1930â€“2021): an unsurpassable mentor, counselor, and child health advocate. Pediatric Research, 2021, , .	2.3	0
121	Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine. Evidence-Based Mental Health, 2010, 13, 84-84.	4.5	0